Background: Enteric glial cells (EGC) play a crucial role in gut barrier maintenance but their role in ulcerative colitis (UC)‐related inflammation is largely unknown. This study investigated EGC and related proteins in patients with UC in inflamed and non‐inflamed segments during clinically active disease and remission following anti‐inflammatory treatment. Methods: Colorectal biopsies were obtained from inflamed and non‐inflamed segments of 14 patients with UC before and after initiating anti‐inflammatory therapy and achieving clinical and endoscopic remission. Control biopsies were collected from 16 healthy controls (HC). EGC markers: glial fibrillary acidic protein (GFAP + ) and S100 calcium‐binding protein β (S100β + ) were assessed by immunofluorescence. Relative estimates of inflammatory proteins in biopsies were analyzed using Olink technology. The EGC cell line CRL‐2690 was exposed to interleukins (IL)‐4 and IL‐6 at varying concentrations and durations, and analyzed by western blotting. Results: EGC GFAP+ and EGC S100β+ were more abundant in inflamed colonic segments during active UC compared to remission ( p < 0.001) and HC ( p < 0.0001). In non‐inflamed segments, EGC GFAP+ decreased significantly with remission ( p < 0.001), whereas EGC S100β+ remained stable. Interleukin stimulation modulated GFAP expression in vitro, with IL‐6 increasing and IL‐4 decreasing in a dose and time‐dependent manner. EGC‐associated proteins, including cytokines, neurotrophic factors and chemokines were elevated in inflamed segments during active UC, normalizing towards HC levels upon remission. Conclusion: Elevated EGC counts, and associated pro‐inflammatory proteins characterize inflamed mucosa during clinical active UC. These novel findings suggest that EGC may be clinically relevant for identifying novel biomarkers for disease monitoring.
Microscopic colitis (MC) is an inflammatory bowel disease characterized by chronic watery diarrhea. Although barrier dysfunction and immune activation are implicated, underlying mechanisms remain unclear. The aim of this study was to characterize enteric glial cells (EGC) and mast cell distribution across MC subtypes, assess treatment effects, and explore EGC-related gene expression and barrier markers. Colonic biopsies from patients with active collagenous colitis (aCC), budesonide-refractory CC (rCC), and active lymphocytic colitis (LC) were compared to irritable bowel syndrome (IBS), ulcerative colitis (UC), and healthy controls (HC). A subset of CC patients was studied during active disease (aCC) and in clinical remission due to budesonide treatment (tCC). Immunofluorescence quantified EGC positive for glial fibrillary acidic protein (EGCGFAP+) and S100 calcium-binding protein B (EGCS100β+), mast cell tryptase, and tight junction proteins. RNA-sequencing assessed EGC-related gene expression. Results showed that EGCGFAP+ were highest in rCC and decreased following budesonide treatment in aCC, whereas EGCS100β+ were highest in aCC, remained unchanged following treatment, resembled IBS, and were reduced compared with UC. Mast cell numbers were higher in aCC than in HC and rCC but remained unchanged following treatment, while mast cell degranulation decreased after treatment. Tight junction proteins were unchanged. RNA-sequencing indicated differential regulation of EGC-related genes. In conclusion, MC shows subtype-specific alterations involving EGC and mast cells, suggesting distinct glial states and differential treatment responsiveness. Our findings support the presence of distinct neuroimmune alterations in CC and LC and highlight EGC as potential contributors to MC pathophysiology.